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93. ABSTRACT
The syndecans are a family of transmembrane heparan sulphate proteoglycans (HSPGs) 
present on most cell types. With the lipid-linked glypicans, syndecans are the major source 
of heparan sulphates on the cell surface. Syndecan-1 is the most studied and best charac-
terized member of the syndecan family. It mediates basic fi broblast growth factor (bFGF) 
binding and activity. Expression of syndecan-1 is down-regulated in many cell transforma-
tion models. The extracellular syndecan-1 domains can be shed from the cell surface in a 
highly regulated process called ectodomain shedding, giving rise to soluble syndecan-1 that 
can be measured from the serum.
Tissue expression of syndecan-1 is associated with a favourable outcome in several types of 
human squamous cell carcinomas (SCCs) when assessed with immunohistochemistry. We 
found low syndecan-1 expression to be associated with unfavourable overall survival in a 
univariate analysis in a series of 175 patients diagnosed with SCC of the head and neck (study 
I; P=0.001), in another series of 116 patients who had SCC of the lung (study II; P=0.026), 
and in a third series consisting of 44 patients with logoregional SCC of the larynx or the 
hypopharynx (study V; P=0.027). Syndecan-1 expression was generally higher in well dif-
ferentiated head and neck and lung cancers than in moderately or poorly differentiated cancer 
(studies I and II). Syndecan-1 expression was an independent prognostic factor in a multivari-
ate survival analysis that contained the histological grade as a covariate in SCC of the head 
and neck (P=0.016; relative risk, RR 1.9; 95% confi dence interval, CI, 1.2–3.1, study I).
The infl uence of soluble serum syndecan-1 concentration on outcome was evaluated in a 
series of 134 patients diagnosed with small cell lung cancer (SCLC, studies III and IV), in 
another series of 138 patients diagnosed with non-small cell lung cancer (NSCLC, study 
III), and in a third series consisting of 44 patients with SCC of the head and neck (study 
V). A high serum syndecan-1 level turned out to be an independent prognostic factor both 
in NSCLC (P=0.011, RR 1.8, 95% CI 1.1–3.1, study III) and in SCLC (P=0.044, RR 1.68, 
95% CI 1.02–2.77, study IV). A high serum bFGF level was associated with poor prognosis 
in NSCLC in a multivariate survival analysis (study III, P=0.056, RR 1.6, 95% CI 1.0–2.7), 
and in SCC of the head and neck in a univariate survival analysis (study V, P=0.043). Pa-
tients with head and neck cancer whose serum syndecan-1 level decreased more than 10% 
from the pretreatment level had a more favourable survival than those whose serum levels 
remained stable or increased (study V, P=0.0069). Recurrent head and neck cancer was 
found to be associated with elevated serum syndecan-1 levels as compared to the levels 
measured 3 months after the completion of the primary treatment (study V). This fi nding 
suggests that a part of serum soluble syndecan-1 originates from the tumour tissue. 
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4. INTRODUCTION
Heparan sulphate proteoglycans (HSPGs) are widely distributed in mammalian tissues and 
they participate in a variety of normal tissue functions. HSPGs are essential for normal tis-
sue growth and development. Their expression is regulated during organ development and 
altered in various pathophysiological processes including cancer. The syndecans are a fam-
ily of transmembrane HSPGs, which, together with the lipid-linked glypicans, are the major 
source of heparan sulphate on cell surfaces (reviewed by Bernfi eld et al., 1999). 
The syndecan family consists of 4 members (syndecan-1, syndecan-2, syndecan-3, and 
syndecan-4) encoded by four different genes. Each member has its own tissue distribution 
(reviewed by Bernfi eld et al., 1992); syndecan-1 is expressed mostly by epithelial cells. Its 
expression is altered in malignant tumours and decreases as an in situ carcinoma progresses 
to an invasive carcinoma (reviewed by Sanderson, 2001, and by Sasisekharan et al., 2002). 
Basic fi broblast growth factor (bFGF) is a heparin-binding molecule that binds to synde-
cans and remains biologically active when immobilized in the cell matrix via the heparan 
sulphate chains of syndecan (Salmivirta et al., 1992a). 
In clinical series syndecan-1 expression, as detected by immunohistochemistry, has been 
found to be associated with a poor histological grade of cancer differentiation in a few types 
of human cancer, and a low syndecan-1 expression in cancer tissue has been associated with 
poor outcome in head and neck cancer, mesothelioma, gastric cancer, cholangiocarcinoma, 
and NSCLC (Inki et al., 1994a; Pulkkinen et al., 1997; Kumar-Singh et al., 1998; Wiksten 
et al., 2000; Harada et al., 2003; Shah et al., 2004). The extracellular syndecan-1 domain 
can be shed from the cell surface into the extracellular fl uid by ectodomain shedding (Kim 
et al., 1994; Fitzgerald et al., 2000). The serum syndecan-1 concentrations found in healthy 
individuals are, however, low (Seidel et al., 2000a). A high soluble serum syndecan-1 con-
centration has been found to have adverse prognostic value in multiple myeloma (Seidel et 
al., 2000a)
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5. REVIEW OF THE LITERATURE
5.1. Cell surface heparan sulphate proteoglycans
Proteoglycans (PGs) are ubiquitous molecules that carry  sulphated carbohydrate side chains 
called glycosaminoglycans (GAG). PGs consist of a diverse group of proteins that are 
grouped together mainly because they contain  GAG. There are four main types of GAGs: 
heparin/heparan sulphate, chondroitin sulphate/dermatan sulphate, keratan sulphate, and 
hyaluronic acid (reviewed by Ruoslahti, 1988; and by Kjellen and Lindahl, 1991). HSPGs 
are composed of a core protein with at least one covalently bound GAG chain (reviewed by 
Kjellen and Lindahl, 1991). These chains contain regions with a high level of sulfation and 
epimerization, sequences with alternating N-sulfation and N-acetylation, and unmodifi ed 
domains which are mostly N-acetylated and contain little sulphate (reviewed by Tumova 
et al, 2000). 
According to their predominant cellular location, PGs can also be classifi ed as cell sur-
face PGs (e.g. syndecans, glypicans, betaglycan, CD44), extracellular matrix PGs (e.g. 
perlecan), and intracellular granule proteoglycans (e.g. serglycin, reviewed by Kjellen and 
Lindahl 1991). Two major groups of cell surface PGs are the transmembrane syndecans 
(reviewed by Bernfi eld et al., 1992; and by Carey, 1997) and glycosylphosphatidylinositol-
anchored glypicans (David et al., 1990). CD44E, which is a splice variant of  the matrix 
receptor CD44 with a single HS chain and betaglycan, can act as a ”part time” PG (Brown 
et al., 1991; Lopez-Casillas et al., 1991). These proteins may bear heparan sulphate chains 
in some proportion or under some conditions. 
Cell surface HSPGs bind extracellular proteins and form signaling complexes with recep-
tors. HSPGs immobilize proteins at the cell surface and mediate protein internalization. 
HSPGs have a role in cell adhesion and migration. These processes may involve intact 
PG and require both heparan sulphate-ligand-binding and direct or indirect interactions of 
the core protein with cytoskeletal and/or signaling molecules (reviewed by Tumova et al., 
2000). The cell surface HSPGs bind to various ligands such as growth factors, cytokines, 
cells, extracellular matrix components and microbes (reviewed by Bernfi eld et al., 1999; 
and by Tumova et al., 2000). 
The cell surface HSPGs can also act as coreceptors for soluble growth factors (reviewed 
by Sasisekharan et al., 1997; by Faham, 1998; by Gallagher, 2001; and by Mohammadi 
et al., 2005). Growth factors that bind to heparan sulphate or heparin include the family 
of FGFs (reviewed by Gallagher, 2001; and by Wu et al., 2003), hepatocyte growth factor 
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(HGF) (Lyon and Gallagher, 1994), platelet-derived growth factor (PDGF) (Feyzi et al., 
1997), heparin-binding epidermal growth factor (EGF)-like growth factor (Higashiyama et 
al., 1993), and vascular endothelial growth factor (Neufeld et al., 1999). In addition, γ-in-
terferon (Lortat-Jacob et al., 1995) and various chemokines (McFadden and Kelvin, 1997) 
bind to HSPGs. HSPGs and heparin are known to prevent blood coagulation by interfering 
with thrombin processing fi brinogen to fi brin (Conrad, 1998; Bourin and Lindahl, 1993) 
and to be involved in lipid metabolism (Fuki et al., 1997; Rosenberg et al., 1997). HSPGs 
also participate in the catabolism of proteins implicated in Alzheimer’s disease (Donahue et 
al., 1999) and are implicated in the binding of various pathogens and mediating their inva-
sion into host cells (reviewed by Rostand and Esko, 1997; Sawitzky, 1996). Some of the 
cell surface HSPGs (e.g. syndecans and glypicans) undergo regulated proteolytic cleavage 
near the plasma membrane and release their ectodomains as soluble intercellular regulators 
resulting in soluble PGs that probably retain all the binding propeties of their parent mol-
ecules (reviewed by Bernfi eld et al., 1999).
5.2. The syndecan family
Syndecans are type I transmembrane proteins that share distinctive structural features (re-
viewed by Bernfi eld et al., 1992; by David, 1993; and by Carey, 1997). They have diverse 
functions ranging from participation in cell-cell adhesion, regulation of cell signaling by 
growth factors, and organization of cell-matrix adhesions. There are four genes in the verte-
brate syndecan family that each encode one type of syndecan, i.e. syndecan-1 (“syndecan”, 
CD138), syndecan-2 (fi broglycan), syndecan-3 (N-syndecan) and syndecan-4 (ryudocan, 
amphiglycan). 
The ectodomain of all syndecan core proteins has 3 to 5 putative GAG attachment sites 
near the N-terminus that are usually heparan sulphate substituted, although some members 
can be substituted with chondroitin or dermatan sulphate. In addition, syndecan-1 and -3 
proteins have 2 or 3 putative membrane-proximal GAG attachment sites. The transmem-
brane domains of syndecans are highly homologous. Within the small cytoplasmic domains 
there are 2 regions of high sequence conservation (the conserved regions C1 and C2) split 
by an interventing sequence (V region) that is specifi c to individual syndecans (reviewed 
by Woods and Couchman, 1998, by Woods, 2001, and by Beauvais and Rapraeger, 2004). 
These highly conserved domains bind to a number of cytoplasmic and cytoskeletal proteins 
(reviewed by Zimmermann and David, 1999). 
All syndecans have a COOH-terminal FYA sequence in C2 that can interact with the PDZ 
domains of several protein (post-synaptic density 95, PSD-95; discs large, Dlg; and zonula 
occludens-1, ZO-1 domains). The fi rst PDZ protein shown to interact with syndecans was 
13
syntenin (Asundi et al., 1995; Grootjans et al., 1997 & 2000; Zimmermann et al., 2001). 
Other PDZ domain proteins that bind the syndecans include CASK/Lin-2 (Cohen et al., 
1998; Hsueh et al., 1998), synbindin (Ethell et al., 2000), and synectin (Gao et al., 2000). 
The C1 region interacts with the members of src/cortactin signaling pathway (syndecan-3, 
reviewed by Couchman et al., 2001, by Woods and Couchman, 2000 and by Tumova et 
al., 2000), ezrin (syndecan-2, Granes et al., 2000), and syndesmos (syndecan-4, Baciu et 
al., 2000). The V regions of syndecans are conserved between species but differ between 
syndecans 1 to 4 (Oh et al., 1998; reviewed by Beauvais and Rapraeger, 2004).  Structure 
of syndecan-1 is shown in Figure 1.
Figure 1. Schematised structure of syndecan-1 at the cell surface and the shed syndecan-
1 ectodomain. A) The 310-amino-acid long core protein of human syndecan-1 consists of 3 
domains: short cytoplasmic domain, transmembrane domain and extracellular domain (ecto-
domain). The ectodomain contains 5 possible GAG attachement sites, which are at positions 
37, 45, 47, 206 and 216 (Mali et al., 1990). The epitope of B-B4 has been localized between 
amino acids 90–93 and the epitope of 104–9 between amino acids 88–110. B) Syndecan-1 can 
be cleaved from the cell surface near the plasma membrane and released into the extracellular 
space in a  process known as shedding. 
Core protein 
GAG
B-B4104-9
Cell surface
Core protein 
GAG
B-B4104-9
A
B
proteolytic cleavage site ectodomain transmembrane 
domain 
cytoplasmic domain
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Virtually all cell types express at least one form of syndecan, but most express multiple 
syndecans. Syndecan expression is highly regulated and distinctive patterns of syndecan 
expression characterize individual cell types, tissues and development stages. In general, 
syndecan-1 is the major syndecan in epithelial cells, syndecan-2 in fi broblasts, syndecan-3 
in neuronal tissues and interestingly, syndecan-4 is present in a range of cell types including 
fi broblasts, epithelial, and smooth muscle cells (reviewed by Bernfi eld et al., 1992, and by 
Woods, 2001).
5.3.  Syndecan-1
5.3.1. A short history of syndecan-1
Syndecan-1 is the most studied member of the syndecan family. It was originally isolated 
from a mouse mammary epithelial cell line (Rapraeger and Bernfi eld, 1983), and was later 
identifi ed as a developmentally regulated type-I-transmembrane protein that binds to the 
extracellular matrix components surrounding epithelial cells (Rapraeger and Bernfi eld, 
1983; Koda and Bernfi eld, 1984; Saunders and Bernfi eld, 1988). The protein was named 
as syndecan from the Greek word syndein (to bind together) as it was thought to link the 
cytoskeleton to the interstitial matrix (Saunders et al., 1989). Syndecan-1 was found to be 
a hybrid PG, containing both heparan sulphate and chondroitin sulphate chains attached to 
the protein core (Rapraeger et al., 1985), but later it was found that syndecan-1 may also 
carry heparan sulphate alone (Sanderson et al., 1989; Salmivirta et al., 1991). Saunders 
et al. cloned and sequenced full-length syndecan-1 cDNA using a library of mammary 
epithelial cells, and assessed the expression of its mRNA in various tissues (1989). The 
311-amino acid core protein was found to have a unique sequence that contained several 
structural features consistent with its role as a matrix anchor and as an acceptor of two 
distinct types of GAG chains. Human syndecan-1 gene was mapped to chromosome 2p23 
(Ala-Kapee et al., 1990).
5.3.2. Tissue expression of syndecan-1
In the developing mouse syndecan-1 expression is detected initially at the 4-cell stage (Suth-
erland et al., 1991).  After gastrulation, highest expression is found in the ectoderm and in 
the endoderm that differentiate into syndecan-1 positive epithelial stuctures found in adults 
(Hayashi et al., 1987; Sutherland et al., 1991). Syndecan-1 expression is found in various 
developing epithelia such as the epidermis, and the mammary epithelium (Trautman et al., 
1991). During embryonic development syndecan-1 is also expressed in the mesenchyme 
at sites of epithelial-mesenchymal interactions e.g. in the developing teeth (Thesleff et al., 
15
1988; Vainio et al., 1991), the kidney (Vainio et al., 1992), the lung (Brauker et al., 1991), 
the hair follicles (Trautman et al., 1991), and the limb (Solursh et al., 1990).
In a normal adult syndecan-1 is abundantly expressed on epithelial tissues, where the strong-
est expression is found in the stratifi ed epithelia at the cell-cell contacts between epidermal 
keratinocytes (Hayashi et al., 1987; Inki et al., 1991). In keratinocytes, syndecan-1 is local-
ized at the cell surface, predominantly in the suprabasal cell layers, whereas the basal cell 
layer shows only weak expression. Fibroblasts (Elenius et al., 1992) and endothelial cells 
(Elenius et al., 1991; Kojima et al., 1992) express small amounts of syndecan-1. Syndecan-
1 is also present on pre-B cells (Sanderson et al., 1989), plasma cells (Hayashi et al., 1987), 
myeloma cells (Ridley et al., 1993; Wijdenes et al., 1996), and Leydig cells (Hayashi et 
al., 1987). Expression of syndecan-1 on B-cells is regulated by interleukin-6 (Sneed et al., 
1994; Götte et al., 2002; Götte, 2003), and it is lost in pre-B-cells immediately before the 
mature B-cells are released into the circulation (Sanderson et al., 1989). 
In the process of wound healing syndecan-1 is transiently decreased in keratinocytes mi-
grating into the wound, whereas it is increased in the keratinocytes proliferating at the 
wound margin and in endothelial cells within the granulation tissue, while syndecan-4 is 
induced on the fi broblasts that form granulation tissue (Elenius et al., 1991; Gallo et al., 
1996). A reduction of syndecan-1 immunostaining has been found in the reparative epitheli-
um in infl ammatory bowel disease (Day et al., 1999a), and the loss of syndecan-1 may lead 
to impaired binding of bFGF and a reduced rate of ulcer healing (Day and Forbes, 1999b). 
Tanabe and coworkers (1999) studied syndecan-1 expression in gastric mucosal ulcers, and 
found enhanced expression in elongated regenerative foveolar cells at the healing ulcer 
margins and within the early scar tissues. Balloon catheter induced vascular wall injury 
increases syndecan-1 expression in carotic artery smooth muscle cells (Cizmeci-Smith et 
al., 1997a; Wang et al., 1997).  
Expression of syndecan-1 decreases in cellular transformation models. When syndecan-1 
was transfected into S115 mouse mammary tumour cells, the re-expression of syndecan-1 re-
stored the epithelial morphology of the S115 cells (Leppä et al., 1992). Conversely inhibition 
of syndecan-1 expression in NMuMG cells caused them to become mesenchyme-like (Kato 
et al., 1995). Liu and coworkers (1997) irradiated the mouse skin, which resulted in loss of 
syndecan-1 expression. Syndecan-1 expression is downregulated or lost in a number of epi-
thelial cancers, and in premalignant lesions of the uterine cervix and the oral mucosa. Such a 
loss may be an early genetic event contributing to tumour progression (Inki et al., 1992, Inki 
et al., 1994b & 1994c; Hirabayashi et al., 1998; Nakanishi et al., 1999; Rintala et al., 1999; 
Soukka et al., 2000; Sanderson, 2001; Numa et al., 2002). In premalignant areas of stratifi ed 
epithelia syndecan-1 is lost from the basally located, atypical cell layers (Inki et al., 1991).
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5.3.3. Regulation of syndecan-1 expression
Syndecan-1, like other members of the syndecan family, is expressed in a distinct cell-, tis-
sue-, and development-specifi c pattern (Kim et al., 1994). Expression of syndecan-1 is also 
modifi ed in pathological conditions. The molecular mechanisms that are responsible for the 
regulation of syndecan-1 expression are under active investigation. 
Expression of syndecan-1 can be induced in cultured cells by treatment with various growth 
factors and cytokines. bFGF alone (Jaakkola et al., 1997) or in a combination with trans-
forming growth factor β (TGF-β)  increased syndecan-1 expression in 3T3 cells (Elenius et 
al., 1992). In vascular smooth muscle cells PDGF or angiotensin II stimulated syndecan-1 
expression (Cizmeci-Smith et al., 1993). PDGF and TGF-β increased syndecan-1 expres-
sion in human periodontal fi broblasts and osteoblasts, while IL-1b decreased the expres-
sion (Worapamorn et al., 2002). Gallo and coworkers (1994) showed induced syndecan-1 
expression in cultured mouse mesenchymal cells during wound repair using a proline-rich 
antimicrobial peptide (PR-39) that is released by infl ammatory cells entering the skin. In 
endothelial cells, in turn, syndecan-1 expression was decreased by tumour necrosis factor-α 
(Kainulainen et al., 1996). 
In general, levels of syndecan-1 synthesis correlate with syndecan mRNA levels, which 
suggests that its regulation is mainly controlled at transcriptional level. The upstream 
sequences of the syndecan-1 gene have promoter activity and contain TATA and CAAT 
boxes as well as a variety of other potential binding sites for transcription factors, in-
cluding Sp1, NF-kappa B, MyoD, and Antennapedia (Hinkes et al., 1993; Vihinen et al., 
1996). Syndecan-1 expression is down-regulated during myogenesis. It is modulated by 
bFGF and TGF-β, which when added together induced syndecan-1 expression.  Retinoic 
acid, an inducer of myogenesis, inhibited syndecan-1 expression and abolished the ef-
fect of the growth factors via a proximal promoter region (Larrain et al., 1997). The 
DNA-binding protein encoded by Wilms’ tumour suppressor gene wt 1 has been found 
to function as a transcriptional activator of syndecan-1 expression (Cook et al., 1997). 
A far upstream enhancer FGF-2 inducible response element (FiRE) on the syndecan-1 
gene was shown to mediate syndecan-1 induction by FGFs in fi broblasts and by EGF in 
keratinocytes, but not vice versa (Jaakkola et al., 1997; Jaakkola et al.,1998a). During 
wound healing the activation of FiRE is seen in the migrating keratinocytes and might be 
responsible for the induced syndecan-1 expression in these cells (Jaakkola et al., 1998b); 
syndecan-1 expression is increased up to 20-fold in keratinocytes during wound healing 
(Elenius et al., 1991). Syndecan-1 induction during wound healing may be enhanced by 
syndecan-inducing antimicrobial peptides released into the wound from infl ammatory 
cells (Gallo et al., 1996).
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Syndecan-1 expression may also be regulated post-transcriptionally. Syndecan-1 expres-
sion was strongly induced in stratifying keratinocytes (Sanderson et al., 1992a) and in mes-
enchymal cells condensing during kidney formation (Vainio et al., 1989a), but no simulta-
neous change in the mRNA levels was found. Similarly, thioglycollate-elicited peritoneal 
mouse macrophages contain 9-fold more syndecan-1 mRNA than untreated macrophages, 
but this mRNA is not translated into the syndecan-1 core protein unless the cells are treat-
ed with agents that raise the intracellular cAMP levels (Yeaman and Rapraeger, 1993). 
Post-translationally regulated syndecan-1 expression also occurs (Sanderson and Bernfi eld, 
1988). Shedding of the extracellular domain of syndecan-1 from the cell surface provides 
an additional potential level for functional control (Jalkanen et al., 1987).
5.3.4. Shedding of syndecan-1 and soluble syndecan-1
A small proportion of membrane-anchored proteins undergo regulated endogenous proteo-
lytic cleavage resulting in release of their ectodomains as soluble intercellular regulators in 
the process of ectodomain shedding (Hooper et al., 1997; Werb and Yan, 1998). Shedding 
liberates these ectodomains as soluble molecules and at the same time their concentration at 
the cell surface decreases. The released fragments retain the ability to bind the same extra-
cellular ligands as the heparan sulphate chains at the cell surface, and they can compete for 
the same ligands as their cell surface counterparts. Since syndecan-1 shedding is regulated 
in normal cells by physiological mediators, shedding is likely a response to specifi c devel-
opmental and pathophysiological cues (Fitzgerald et al., 2000). 
The syndecan-1 core protein is cleaved on the cell surface at the extracellular  juxtam-
embrane site (Figure 1), and the proteolytic activity responsible for accelerated shedding 
differs from that involved in constitutive shedding of syndecan ectodomains (Fitzgerald 
et al., 2000). The intact ectodomains of each mammalian syndecan and the Drosophila 
syndecan are constitutively shed into the conditioned media of cultured cells (Kim et al., 
1994; Spring et al., 1994) as part of normal cell surface turnover (Yanagishita and Hascall, 
1992; Yamagata et al, 1993; Yanagishita, 1998), but the syndecan-1 concentrations found 
in sera of healthy individuals are low (Seidel et al., 2000a). Shed syndecan-1 ectodomains 
are found in fl uids that accumulate following tissue injury and infl ammation (Subramarian 
et al., 1997, Kato et al., 1998). Presence of excessive amounts of soluble syndecan-1 ecto-
domain in a wound modulates the function of proteases and inhibits growth factor action, 
which may delay skin wound repair (Elenius et al., 2004). High levels of soluble synde-
can-1 are also found in sera and bone marrow aspirates of patients with multiple myeloma 
(Seidel et al., 2000a). Of note, in vivo soluble syndecan-1 promotes growth of myeloma 
tumours (Yang et al., 2002). 
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Shedding is a highly regulated process and can be induced by various agents, of which the 
phorbol esters are the best characterized agonists (Hooper at al., 1997; Subramanian et al., 
1997). Shedding of syndecan-1 can be enhanced by direct proteolytic cleavage (e.g. by 
thrombin, plasmin, elastase or matrix metalloproteinases; Subramanian et al., 1997; Buc-
zek-Thomas and Nugent, 1999; Endo et al., 2003), and by cellular stress (mechanical, heat 
shock, or hyperosmolarity) involving stress-activated protein kinase pathways (Fitzgerald 
et al., 2000), and by growth factors (Subramanian et al., 1997; Kato et al., 1998). Ectodo-
main shedding is inhibited by the tissue inhibitor metalloproteinase 3 (TIMP), but not by 
TIMP- 1 or -2 (Fitzgerald et al., 2000). 
5.3.5. Functions of syndecan-1 and its association with bFGF
Earlier studies in cell culture conditions have shown that syndecan-1 binds various matrix 
proteins via its heparan sulphate chains, e.g. type I, III, and V collagens (Koda et al., 1985), 
fi bronectin (Saunders and Bernfi eld, 1988), thrombospondin (Sun et al., 1989), tenascin 
(Salmivirta et al., 1991), amphoterin (Salmivirta et al., 1992b), and laminin (Salmivirta 
et al., 1994). Syndecan-1 polarizes to the basolateral surfaces of cultured epithelial cells 
(Rapraeger et al., 1986) and of simple epithelia (Hayashi et al., 1987), and localizes during 
early embryogenesis to the intial sites of extracellular matrix accumulation (Sutherland at 
al., 1991). During tooth development syndecan-1 colocalizes with tenascin (Vainio et al., 
1989b). It is expressed on the developing B-cells only when they are in contact with the 
extracellular matrix (Sanderson et al., 1989), and later it binds B-cells to type I collagen 
(Sanderson et al., 1992b).
Syndecan-1 has potential ability to regulate cytoskeletal organization and to associate with 
the actin cytoskeleton (reviewed by Carey, 1997; and by Yoneda and Couchman, 2003). For 
example, syndecan-1-expressing Raji lymphoid cells (a human lymphoblastoid cell line) 
bind avidly and spread rapidly when they attach to extracellular matrix ligands that con-
tain heparan sulphate-binding domains (Lebakken et al., 2000; McQuade and Rapraeger, 
2003). Transfection of syndecan-1 into COS-7 cells stimulates cell migration (Adams et al., 
2001). Ectopic expression of syndecan-1 in Schwann cells, which normally do not express 
syndecan-1, results in enhanced migration of the cells on fi bronectin and laminin-coated 
substrata, and in a striking reorganization of Schwann cell microfi laments (Carey et al., 
1994).
Syndecans have been suggested to play a role in cell-cell adhesion based on the fi nding that 
several well-characterized cell-adhesion molecules bind to heparan sulphate (reviewed by 
Carey, 1997). Certain myeloma cell lines have lost the ability to synthesize syndecan-1, and 
the loss of syndecan-1 expression correlates with their inability to adhere to one another 
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(Sanderson et al., 1992b). Stable transfection of these cells with syndecan-1 cDNA restores 
the cell-to-cell adhesion activity (Stanley et al., 1995). In contrast, Raji cells do not undergo 
cell-cell adhesion following their transfection with syndecan-1 (Rapraeger, 1993). 
Syndecan-1 expression is needed for maintenance of a differentiated epithelial phenotype. 
It affects the organization of the actin cytoskeleton and the expression of E-cadherin, which 
is reponsible for epithelial intercellular adhesions (Kato et al., 1995).  When endogenous 
syndecan-1 expression is suppressed by transfection of antisense cDNA, the cell morphol-
ogy changes markedly (Kato et al., 1995). This dramatic change is accompanied by a loss of 
E-cadherin expression. In malignant tumour cells where E-cadherin expression was down-
regulated by using specifi c antisense RNAs, syndecan-1 expression was suppressed, and 
transfection of E-cadherin cDNA resulted in the upregulation of syndecan-1 expression in 
association with an epithelial phenotype and decreased invasiveness (Leppä et al., 1996). 
Epithelial cells that have lost syndecan-1 expression grow readily in soft agar, indicating 
that they have lost their characteristic anchorage-dependent growth (Kato et al., 1995), and 
addition of purifi ed syndecan-1 ectodomain inhibites the growth of carcinoma cells in vitro 
(Mali et al., 1994).
Cell surface syndecan-1 inhibits invasion of tumour cells into 3-dimensional gel composed 
of type I collagen. This inhibition is dependent on the syndecan-1 heparan sulphate chains, 
although a role for the syndecan-1 ectodomain core protein has also been shown. The anti-
invasive effect of syndecan-1 is dramatically reduced by deletion of an ectodomain region 
located close to the plasma membrane, and that this domain is functionally specifi c, be-
cause its deletion did not affect syndecan-1-mediated cell binding to collagen or cell migra-
tion (Langford et al., 2005).
Syndecan-1 functions have also been studied in vivo, which  support in vitro studies. Stud-
ies in syndecan-1-knockout mice revealed an essential role for syndecan-1 in mediating 
cell proliferation and in regulation of integrin expression during wound healing (Stepp et 
al., 2002). Healing problems in these mice were thought to result primarily from defects in 
fi broblast migration, but Stepp et al. showed in 2002 that the delayed healing resulted from 
impaired keratinocyte function. This suggests that syndecan-1 has a role as a regulator of 
gene transcription in keratinocytes and in keratinocyte activation after injury (Stepp et al., 
2002). In contrast,  the role of syndecan-1 in tumour formation appears to be more complex 
as  syndecan-1 does not prevent but supplements Wnt-1-induced mammary tumourigenesis 
in mice (Alexander at al., 2000) and promotes formation of metastases in a mouse lung 
SCC model (Hirabayashi et al., 1998).
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Many growth factors bind to heparin or heparan sulphate, including the FGF family mem-
bers (Nugent and Iozzo, 2000; Ornitz and Itoh, 2001). Over 20 mammalian FGFs have been 
characterized to date, but bFGF remains the most studied member of the family. Members 
of each of the FGF subclass are capable of binding to one or more of 4 different FGF re-
ceptors (FGFR1-4). Binding of FGFs to heparan sulphate is needed for signal transmission 
through the FGF high-affi nity receptors (Rapraeger et al., 1991; Yayon et al., 1991). It has 
been challenging to determine the role of syndecan-1 in bFGF receptor signaling. It was 
fi rst found that enhanced syndecan-1 expression in cultured cells strongly inhibited bFGF-
induced cell proliferation (Mali et al., 1993). Later, purifi ed preparations of soluble synde-
can-1 were found to inhibit bFGF-receptor binding in cell free assays (Avierez et al., 1994). 
Finally, syndecan-1 expression was shown to stimulate FGFR-1 signaling (Steinfeld et al., 
1996) and to mediate bFGF binding and activity (Filla et al., 1998). A strong infl uence of 
syndecan-1 expression on cell responsiveness to bFGF has been shown in in vitro models, 
where syndecan-1 expression has resulted in a several-fold increase in cell sensitivity to 
bFGF (Larrain et al., 1998). Syndecans have been implicated as modulators of the bFGF 
receptor-binding affi nity, giving rise to decreased bFGF binding as a response to increased 
cell density in a culture (Richardson et al., 1999). Expression of syndecan-1 core protein in 
breast carcinoma tissue correlates well with the bFGF receptor complex formation in situ, 
suggesting that in breast carcinomas bFGF receptor binding is infl uenced by the syndecan-
1 core protein levels (Mundhenke et al., 2002). Soluble syndecan-1 ectodomains found in 
infl ammatory fl uids appear to act as inhibitors of bFGF activity (Kato et al., 1998). 
Syndecan-1 modulates hepatocyte growth factor (HGF) activity in myeloma. Purifi ed solu-
ble syndecan-1 can displace HGF from myeloma cell surface suggesting that soluble syn-
decan-1 may act as a carrier of HGF in vivo (Seidel et al., 2000b). Soluble syndecan-1 
promotes growth of myeloma tumours in vivo, and both in in vitro and in vivo studies the 
syndecan-1 ectodomain promotes dissemination of myeloma cells (Yang et al., 2002). 
Syndecan-1 also binds extracellular ligands that are neither growth factors nor cell adhesion 
molecules. These include lipoprotein metabolism proteins. Syndecan-1 may mediate LDL 
receptor-independent clearance of lipoproteins via binding to lipoprotein lipase, an enzyme 
involved in triglyceride catabolism (Fuki et al., 1997). Another class of enzymes that may 
be regulated by heparin/heparan sulphate is certain serine proteases and their inhibitors 
(serpins). Studies on the binding activity of antithrombin III (AT III), a serpin that inhibits 
thrombin and other coagulation proteases, revealed that thrombin increased synthesis of 
syndecan-1 that in turn exhibited high-affi nity AT III binding (Cizmeci-Smith and Carey, 
1997b). Syndecan-1 has also been found to mediate the invasion of a host by pathogenic 
cells such as Neisseria gonorrhoeae (Freissler et al., 2000).
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It has been suggested that syndecan-1 expression may prevent bone destruction, since syn-
decan-1 has been found to increase osteoblast development and inhibit osteoclast formation 
(Dhodapkar et al., 1998).
5.3.6. Clinical signifi cance of syndecan-1
Based on the studies carried out in vitro and in experimental models, it can be anticipated 
that syndecan-1 expression may infl uence the clinical behaviour of human cancer. HSPGs 
regulate several aspects of cancer progression including tumorigenesis and metastasis (re-
viewed by Blackhall et al., 2001; and by Sasisekharan et al., 2002), and  in squamous 
cell carcinomas syndecan-1 expression appears to be associated with maintenance of the 
differentiated morphology of cancer and inhibition of cancer invasiveness. Expression of 
syndecan-1 is sometimes downregulated in tumours, in premalignant lesions, and as an in 
situ carcinoma processes to an invasive carcinoma (Inki and Jalkanen, 1996; Nakanishi et 
al., 1999; Rintala et al., 1999; Soukka et al., 2000; Sanderson , 2001). However, in some 
experimental models syndecan-1 has promoted tumorigenesis and formation of metastases 
(Hirabayashi et al., 1998; Alexander et al., 2000).
5.3.6.1. Lung cancer
Several human lung cancer cell lines express syndecan-1 (Nackaerts et al., 1997; Toy-
oshima et al., 2001; Nanki et al., 2001, Matsunaga et al., 2002). Nackaerts and coworkers 
found all 3 squamous cell lung cancer cell lines tested to be positive for syndecan-1, and 
2 of the 3 adenocarcinoma cell lines investigated also showed marked expression. Similar 
results were reported by Toyoshima and coworkers, who detected syndecan-1 mRNA in 
both NSCLC and SCLC cell lines. In the study carried out by Nanki and coworkers (2001), 
syndecan-1 expression was stronger in NSCLC than in SCLC cell lines. In mouse cell lines 
derived from SCC, increased syndecan-1 expression was associated with the rate of cell 
proliferation and it was reported to promote formation of metastases (Hirabayashi et al., 
1998). Syndecan-1 gene transcripts were present in lung cancer tissue and in the peripheral 
blood of lung cancer patients, which might support the authors’ hypothesis that isolation of 
syndecan-1 mRNA from the blood may aid in early detection and staging of lung cancer, 
and follow-up of lung cancer patients (Matsunaga et al., 2002).
Lung tumours have been found to express syndecan-1. In general, NSCLCs stain more of-
ten positively for syndecan-1 than SCLCs, SCCs of the lung express more often syndecan-1 
than adenocarcinomas of the lung, and poorly differentiated tumours express markedly less 
syndecan-1 than better differentiated ones (Nackaerts et al., 1997; Toyoshima et al., 2001). 
Linnerth et al. (2005) found that syndecan-1 levels were elevated both in murine and human 
lung adenocarcinomas and SCCs. Importantly, the high syndecan-1 levels could already be 
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detected in small and node-negative lung tumours suggesting that syndecan-1 could serve 
as an early marker for lung tumour development. In line with the studies presented in this 
theses, one recent study comprising a series of 78 NSCLC patients found tumour tissue 
syndecan-1 expression to be associated with favourable survival, and tumour syndecan-
1 expression turned out to be an independent prognostic factor in a multivariate survival 
analysis (Shah et al., 2004). 
Syndecan-1 is strongly expressed in the epithelial type of mesothelioma and patients with 
strong syndecan-1 positive tumours have longer survival than those whose tumours show 
weak or negative staining for syndecan-1 (Kumar-Singh et al., 1998). Syndecan-1 expres-
sion has been studied as a marker for distinguishing adenocarcinoma from epitheloid me-
sothelioma. Adenocarcinoma cells were found to produce more mRNA for syndecan-1, 
whereas cells derived from the mesothelium expressed WT1, biglycan, and larger amounts 
of syndecan-2 (Dobra et al., 2000; Gulyas and Hjerpe, 2003).   
5.3.6.2. Head and neck carcinoma
Syndecan-1 expression is enhanced during normal differentiation of cultured human ke-
ratinocytes derived from the oral mucosa, while malignant transformation of keratinocytes 
is associated with suppression of syndecan-1 expression (Inki et al., 1994b). In premalig-
nant lesions, such as dysplastic oral epithelium, syndecan-1 expression is downregulated 
compared to normal oral squamous cell epithelium (Soukka et al., 2000). When paraffi n-
embedded or frozen tissues of SCC of the head and neck is used as the starting material, 
strong immunoreactivity for syndecan-1 has been found to be associated with a higher his-
tological grade of differentiation (Inki et al., 1994a; Pulkkinen et al., 1997; Mikami et al., 
2001; Klatka, 2002); strong syndecan-1 expression is more common in well or moderately 
differentiated carcinomas than in poorly differentiated ones. 
There are few data available on the prognostic value of syndecan-1 expression in SCC of 
the head and neck. In the fi rst study reported that addressed the question of syndecan-1 as 
a prognostic factor in invasive SCCs of the head and neck, Inki and her coworkers (1994a) 
found that patients with a syndecan-1-positive tumour had higher overall and recurrence-
free survival rates than patients who had tumours showing weak or negative staining for 
syndecan-1 in a small series consisting of 29 patients. Similar results were later found in 2 
studies that involved 100 and 48 patients with SCC of the larynx (Pulkkinen et al., 1997; 
Klatka, 2002). There are no data available on the prognostic value of soluble syndecan-1 in 
SCC of the head and neck.
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5.3.6.3. Other malignancies
Several studies have addressed the role of syndecan-1 expression in other malignancies 
than cancers of the lung or the head and neck. The most studied single tumour type is B-cell 
lymphoid malignancies (reviewed by Sanderson and Borset, 2002). Syndecan-1 was de-
tected on human myeloma cells by Western blotting in 1993 (Ridley et al., 1993), and it was 
subsequently identifi ed on the myeloma cell surface by fl ow cytometry using a monoclonal 
antibody (Wijdenes et al., 1996). Syndecan-1 can also be found on the myeloma cells that 
circulate in the blood (Witzig et al., 1998; Bayer-Garner et al., 2001). Syndecan-1 has been 
considered to be a reliable and sensitive marker for plasmocytoma  independent of cyto-
logical differentiation (Bayer-Garner et al., 2003). Syndecan-1 is expressed by many lym-
phomas. It is expressed on the Reed-Sternberg cells from patients with classic Hodgkin’s 
disease, but not on the Reed-Sternberg cells present in the nodular lymphocyte predominant 
Hodgkin’s disease (Carbone et al., 1997). It is currently somewhat controversial whether 
syndecan-1 is expressed on malignant cells of B-cell chronic lymphocytic leukemia (B-
CLL). Syndecan-1 has been detected by polymerase chain reaction and immunostaining 
in the majority of B-CLL cases examined (Sebestyen et al., 1997; Sebestyen et al., 1999; 
Sutcliffe et al., 2000), but one study found only 1 of the 39 B-CLL cases examined to stain 
positively for syndecan-1 (Witzig et al., 1998). 
Most myeloma cells in culture shed syndecan-1 ectodomain, which in turn induces apop-
tosis and inhibits the growth of the myeloma cells (Dhodapkar et al., 1998). In myeloma 
patients the levels of serum syndecan-1 ectodomain are elevated as compared to controls, 
and high serum syndecan-1 concentrations are associated with higher levels of  marrow 
plasmocytosis, high serum β2-microglobulin and paraprotein levels, and a large tumour 
mass (Dhodapkar et al., 1997). High serum levels of syndecan-1 have been reported to be 
a strong indicator of poor outcome and an independent prognostic marker in multiple my-
eloma (Seidel et al., 2000a; Aref et al., 2003; Kyrtsonis et al., 2004).
Studies based on immunohistochemistry and targeting on several types of human cancers 
including carcinoma of the breast (Stanley et al., 1999), uterine cervix (Inki et al., 1994c; 
Rintala et al., 1999), and colon and rectum (Day et al., 1999c), and basal cell and squamous 
cell skin carcinomas (Bayer-Garner et al., 1999; Bayer-Garner et al., 2000; Bayer-Garner 
et al., 2001; Mukunyadzi et al., 2002) suggest that syndecan-1 expression is dimished in 
malignant lesions as compared to premalignant and benign ones. In infi ltrating ductal breast 
carcinoma staining for syndecan-1 is decreased as compared with the ductal epithelium 
of the normal breast and stromal-epithelial breast neoplasms. Unexpectedly, in carcinoma 
samples strong staining for syndecan-1 is present both within the connective tissue and on 
stromal cell surfaces, whereas syndecan-1 expression is absent in the stroma of the normal 
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breast and stromal-epithelial neoplasms (Stanley et al., 1999). Recently, two studies have 
concluded tumour syndecan-1 expression to be associated with a poor outcome in breast 
cancer (Barbareschi et al., 2003; Leivonen et al., 2004). 
In primary invasive cervical carcinoma syndecan-1 expression was found to be associated 
with the histological differentiation grade and presence of squamous histology, but not with 
the clinical outcome (Rintala et al., 1999). In hepatocellular and colorectal carcinoma loss 
of syndecan-1 expression was associated with a low grade of differentiatiation and presence 
of metastases (Levy et al., 1996; Matsumoto et al., 1997; Fujiya et al., 2001). In contrast to 
the previous tumour types, in pancreatic cancer tissues syndecan-1 expression was found to 
be present at moderate to high levels in the majority of the cancer cells located within the 
tumour mass or in the metastatic lesions, while the expression remained low or moderate 
in the samples containing histologically normal pancreas and chronic pancreatis (Conejo et 
al., 2000). Similar results were obtained when Zellweger and coworkers (2005) evaluated 
the expression of syndecan-1 in advanced prostate carcinoma. They found marked synde-
can-1 overexpression in hormone-refractory prostate cancer and metastatic tissue compared 
to localized prostate cancer.  Among 551 patients with prostate carcinoma syndecan-1 over-
expression was found to predict early recurrence and to be associated with poor tumour-
specifi c survival, a high Gleason grade, high Ki-67 expression, and Bcl-2 overexpression 
(Zellweger et al., 2003). 
Syndecan-1 expression has also been studied by immunohistochemistry in soft tissue tu-
mours, but no correlation with the phenotype was found (Orosz and Kopper, 2001). 
High syndecan-1 expression has been found to correlate with a favourable outcome in 
patients with gastric cancer in a univariate survival analysis, especially in the subgroup of 
patients with stage I disease (Wiksten et al., 2000). Interestingly, patients with positive syn-
decan-1 expression in extracellular matrix had a worse outcome than patients with synde-
can-1-negative stroma (Wiksten et al., 2001). Unlike the normal squamous cell epithelium, 
the normal ovary does not express syndecan-1, and tumour stroma syndecan-1 expression 
was reported to be associated with poor survival in ovarian adenocarcinoma (Davies et al., 
2004).
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6. AIMS OF THE STUDY
The aims of the present thesis were:
  • To investigate the expression and prognostic signifi cance of syndecan-1 in head and 
neck cancer and in lung cancer (I,II,III,V)
  • To investigate the presence and prognostic signifi cance of serum syndecan-1 and 
bFGF in patients with lung cancer or head and neck cancer (III,IV,V)
  • To study the effect of treatment on serum syndecan-1 levels (V)
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7. MATERIALS AND METHODS
7.1. Patients, tissue and serum samples
Study I. We collected the clinicopathological data of 265 patients with histologically diag-
nosed SCC of the head and neck. Ninety patients were excluded because of insuffi cient data 
or non-available paraffi n-embedded tissue leaving 175 patients in the analysis. The patients 
were treated with surgery and post-operative split-course irradiation in Helsinki University 
Central Hospital in the period 1975 to 1990. The minimum follow-up time of the patients 
after the diagnosis was 2 years. The prognostic signifi cance of syndecan-1 expression was 
studied using paraffi n-embedded tissue samples (TABLE 1).
Study II. The series consisted of 116 patients with operable primary NSCLC squamous cell 
histological type treated with radical surgery in the Helsinki University Central Hospital in 
the period 1982 to 1992. Clinical data were collected and paraffi n-embedded tumour sam-
ples stored for analysis. Expression of syndecan-1 was studied using the paraffi n-embedded 
tissue samples (TABLE 1). The minimum follow-up time of the patients still alive was 12 
months. 
Study III. The series consisted of 207 patients with lung cancer  who had had a serum 
sample collected and stored before cancer treatment. The patients were treated at the De-
partment of Internal Medicine, Oulu University Hospital, in the period 1990 to 1992. We 
excluded cases where no diagnostic biopsy sample was available (n=16) and those with 
histologically unclassifi ed lung cancer (n=7), which left 184 patients in the analysis. Forty-
six patients had SCLC, and the rest of the patients had NSCLC (adenocarcinoma, n=44; 
SCC, n=82; large cell carcinoma, n=9; adenosquamous cell carcinoma; n=3). The median 
follow-up time of the patients still alive was 8.1 years. Syndecan-1 expression was studied 
in formalin-fi xed paraffi n-embedded tumour tissue (TABLE 1). The prognostic signifi cance 
of serum syndecan-1 and serum bFGF was studied from the sera taken prior to the treatment 
(TABLE 2). The serum samples had been stored at –20oC.
Study IV. The series consisted of 88 patients with SCLC who were treated at the Depart-
ment of Internal Medicine, Helsinki University Central Hospital, in 1990 to 1999. The 
patients participated in 2 randomized clinical trials, of which one was a multicenter trial 
to assess the therapeutic value of interferon in the treatment of SCLC (Ruotsalainen et al., 
1999; Ruotsalainen et al., 2000). The total number of patients in these trials was 304, and 
those study participants who had a frozen pretreatment serum sample available and who 
had been treated at the Helsinki University Central Hospital entered  the present study. 
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Serum syndecan-1 concentrations were determined from sera taken prior to initiation of 
chemotherapy (TABLE 2). The sera had been stored at –70oC. Serum samples taken both 
prior to and after the treatment were available in 7 patients (TABLE 2). 
Study V. The study includes 54 patients with SCC of the head and neck who had serum 
samples collected before, during, and after treatment, and who were treated at the Turku 
University Central Hospital in 1997 to 2000. Ten patients were excluded because of insuffi -
cient clinicopathological data. The series consisted of 42 patients with laryngeal carcinoma 
and 2 with hypopharynx carcinoma. Thirty-four patients received radiotherapy; 15 were 
treated with preoperative hyperfractionated radiotherapy (1.6 Gy twice a day, 5 days a 
week, to a total dose of 62 to 68 Gy) followed by surgery. Nineteen patients received radio-
therapy to the primary site to a total dose of 70 Gy given in 35 fractions, and when needed 
the neck was irradiated to a total dose of 50 Gy in 25 fractions excluding the spinal cord 
after 40 Gy. Nine of the patients had surgery only (7 had laser cordectomy, 1 total laryngec-
tomia, 1 hemilaryngectomia). One patient died before any cancer treatment was given.  The 
minimum follow-up time was 13 months for the patients still alive. Syndecan-1 expression 
was studied in 27 available paraffi n embedded tumour samples (TABLE 1). Serum synde-
can-1 and bFGF levels were measured from the samples taken before any cancer treatment 
took place, and from samples collected 3 months after initiation of cancer treatment. Serum 
syndecan-1 levels were also measured at the beginning and at the end of a radiotherapy 
course, at the time of disease progression, and after a second cancer treatment whenever a 
serum sample was available (TABLE 2). 
TABLE 1. Tissue samples examined
Tumour type N Study
Squamous cell carcinoma of the head and neck 
• Larynx
• Tongue
• Oral cavity
• Tonsil
• Hypopharynx
175
 51
 50
 44
 15
 15
I
Squamous cell lung cancer 116 II
Lung cancer 
• Squamous cell carcinoma
• Adenocarcinoma
• Small cell lung cancer 
 45
 36
  6
  3
III
Squamous cell carcinoma of the head and neck 
• Larynx  (vocal cord carcinoma excluded)
• Vocal cord 
 27
 18
  9
V
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TABLE 2. Serum samples analysed for syndecan-1 concentration
Tumour type N Study
Lung cancer
 NSCLC
 SCLC
 Controls 
138
 46
100
III
Small cell lung cancer, prior to therapy
Small cell lung cancer, following therapy
Controls
 88
  7
110
IV
SCC of the head and neck
 Pretreatment sera
 Beginning of radiotherapy
 End of radiotherapy
 Post-treatment sera
 At disease progression
 After second cancer therapy
 
 44
 44
 10
 41
  9
  4
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7.2. Control subjects (studies III and IV)
Serum syndecan-1 levels were measured in 100 (III) and in 110 (IV) male subjects who 
took part in a randomised Finnish population-based prostate cancer screening trial in 1996-
1998 (Määttänen et al., 2001). Prostate-specifi c antigen (PSA) was fi rst measured from the 
sera, and syndecan-1 was assessed from the frozen left-over sera stored for one to 2 months. 
The median age of the controls was 64 (range, 58 to 71).
7.3. Immunohistochemical staining of tissue samples
(studies I, II, III, and V)
Syndecan-1 expression was studied by immunohistochemistry using a mouse monoclonal 
antibody B-B4 generated against extracellular domain of human syndecan-1 (Serotec, Ox-
ford, UK; I-III, V) (Wijdenes et al., 1996) or a rat monoclonal antibody 104–9 (I, II, Figure 
1) directed against  human syndecan-1 core protein aminoacid residues 88 to 110 (Pulk-
kinen et al., 1997; Gattei et al., 1999). The epitope of B-B4 has been localized between the 
amino acids 90 and 93 (Dore et al., 1998). Five µm paraffi n sections were fi rst mounted on 
Vectabond-coated slides. The slides were kept at +37ººC for 24 hours, and after that de-
paraffi nised and dehydrated. They were then incubated with 2% normal goat serum in 1% 
bovine serum albumin (BSA; Sigma, St. Louis, MO, USA) for 20 minutes at room tempera-
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ture (RT) followed by B-B4 or 104–9 antibody in 0.3% BSA overnight at RT at a concentra-
tion of 1:200 (B-B4, I–III), 1:150 (B-B4, V)  or 1:100 (104–9). After washing twice with 
phosphate-buffered saline (PBS), the slides were incubated with Vectastain biotinylated 
anti-mouse IgG (Vector Laboratories, Burlingame, CA, USA) when B-B4 was used, and 
with biotinylated anti-rat IgG (Vector Laboratories) when 104–9 was used in 0.3% BSA 
for 30 minutes at RT. After washing twice with PBS, avidin DH-biotinylated horserad-
ish peroxidase mixture was applied according to the manufacturer’s instructions (Vector 
Laboratories, Burlingame, CA, USA) for one hour at RT. After incubation, the slides were 
washed twice with PBS. For colour reaction the slides were incubated with 0.02% 3-amino-
9-ethylcarbazole (in N,N-dimethylformamide) and 0.1% hydrogen peroxidase in 0.05 M 
acetate buffer, pH 5.0 for 20 minutes at RT, and counterstained in Mayer’s haematoxylin 
before mounting for microscopic examination. Histologically normal human skin was used 
as a positive control, and similarly stained duplicate sections where the primary antibody 
was omitted and replaced by PBS were used as negative controls.
Immunoreactivity for syndecan-1 was classifi ed by assessing visually the percentage of 
syndecan-1 positive tumour cells of all tumour cells in the fi eld (I, II, V). First, the per-
centage of syndecan-1-positive tumour cells of all tumour cells was calculated from 3–5 
representative microscope fi elds per slide (Olympus Optical Company, Tokyo, Japan, ×10 
objective, diameter 2.6 mm, area 5.3 mm2). All selected fi elds contained at least 100 cancer 
cells, and necrotic areas and those with marked infl ammation were excluded. The immuno-
reactivity for syndecan-1 was also classifi ed with regard to the intensity of staining (III, V) 
and cellular localization of staining (V). Staining intensity was classifi ed either as absent 
(–), weak (+), moderate (++), or strong (+++). Cellular localization of staining was assessed 
as diffuse cytoplasmic staining, staining of cell-cell contact sites, or both. Assessment of 
syndecan-1 expression was performed without knowledge of the clinical or survival data.
7.4. Enzyme-linked immunosorbent assay (ELISA)
Peripheral venous blood samples were collected in sterile test tubes, centrifuged at 3,000 G 
for 10 minutes, and then stored at –20oC (III) or at –70oC (IV,V). 
7.4.1. Serum syndecan-1 immunoassay (III–V)
Serum syndecan-1 concentrations were determined using human syndecan-1 ELISA (Dia-
clone Research, Besancon, France) according to the manufacturer’s instructions. The sys-
tem uses a biotinylated monoclonal B-B4 antibody raised against human syndecan-1. The 
detection steps include streptavidin-horseradish peroxidase and tetramethylbenzidine as 
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chromogens. For each analysis 50 µl of serum was used. All analyses and calibrations were 
carried out in duplicate. The calibrations on each microtitre plate included recombinant 
human syndecan-1 standards. Optical densities were determined using a microtiter plate 
reader (Multiscan RC type 351, Labsystems, Helsinki) at 405 nm. The blank was subtracted 
from the duplicate readings for each standard and sample. The serum concentrations are re-
ported as ng/mL.  Syndecan-1 serum levels were determined without knowledge of the sur-
vival or other clinical data. No loss of syndecan-1 immunoreactivity was observed when 9 
samples were subjected to either 3 or 8 freeze-thaw cycles (P=0.89; Friedman test, III). No 
signifi cant difference in serum syndecan-1 concentrations was found when cancer patient 
serum samples stored at –20oC for 4 to 6 years (n=22) and samples stored for 7 to 10 years 
(n=66) were compared, suggesting that there is no major loss of syndecan-1 immunoreac-
tivity during long-term storage as compared with shorter storage (P=0.18; Mann-Whitney 
test, data not shown) (III). 
7.4.2. Serum bFGF immunoassay (III, V)
Serum bFGF concentrations were determined as serum bFGF immunoreactivity using a 
quantitative sandwich enzyme immunoassay technique (Quantikine High Sensitivity Hu-
man FGF basic Immunoassay; R&D Systems, Minneapolis, MN, USA). The system uses a 
solid-phase monoclonal and an enzyme-linked polyclonal antibody raised against recombi-
nant human bFGF. For each analysis, 100 µL of serum was used. All analyses and calibra-
tions were performed as duplicate. The calibrations on each microtiter plate were deter-
mined using a microtiter plate reader (Multiscan RC type 351; Labsystems, Helsinki) at 490 
nm. The blank was subtracted from the duplicate readings for each standard and sample. 
The concentrations are reported as pg/mL. Serum bFGF levels were determined without 
any knowledge of the survival or other clinical data. No association was found between 
serum bFGF concentrations and the duration of storage in serum samples stored at –20oC 
for 11 to 17 years (Salven et al., 1999). 
7.4.3. Serum carcinoembryonic antigen (CEA) immunoassay  (III)
CEA was quantitated in serum using an immunofl uorometric assay (AutoDELFIA; Wal-
lac, Turku). The detection limit of the assay is 0.2 ng/mL. The upper reference limit is 5 
ng/mL.
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7.5. Statistical methods
Statistical analyses were performed using a BMDP computer program (BMDP Statistical 
Software; University of California Press, Los Angeles, CA, USA; I–III) or a StatView 4.02 
computer program (Abacus Concepts Inc., Berkeley, CA, USA; IV and V). Cumulative 
survival was estimated with the product-limit method. The log-rank test was used for com-
parison of survival between groups. The Brookmeyer-Crowley confi dence intervals were 
computed for the median survival times. Frequency tables were analysed with the X2 test. 
Comparison of non-normal distributions was done by computing the Spearman’s correla-
tion coeffi cient, and non-normally distributed parameters between 2 groups were compared 
with the Mann-Whitney test. The relative importance of different variables on survival was 
studied using a Cox multivariate proportional hazards model.
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8. RESULTS
8.1. Expression of syndecan-1 in carcinomas of the head and neck 
and the lung (I, II, III, V)
In these studies a total of 363 tumour samples were immunostained using a monoclonal 
B-B4 anti-syndecan-1 antibody, and 291 of the samples were stained with another anti-
body, 109–4. A majority (n=354) of the tumours were of the squamous cell type, 6 were 
adenocarcinomas, and 3 cases were small cell carcinomas (TABLE 1). Most of the tumours 
showed positive staining for syndecan-1. When the B-B4 antibody was used, from 72% to 
94% of the tumours stained positively for syndecan-1, and when the 104–9 antibody was 
used, 98% (I) and 94% (II) of the samples stained positively. The staining characteristics 
are shown in (TABLE 3). 
The cutoff percentage values in survival analyses varied in each study probably due to the 
type of antibody used to stain the tissue samples and the variations between tumour types 
and series. Our policy was to use more reproducible cut-offs such as the median, and the 
tertiles or quartiles instead of “optimal” percentage values that might have produced smaller 
P values. When the B-B4 antibody was used, the cutoff percentage values chosen were 50% 
(median, study I, head and neck carcinomas), 10% (median, study II, lung carcinomas), and 
10% (lowest tertile, study V, head and neck carcinomas). In study III on lung carcinomas 
the syndecan-1 immunoreactivity was also classifi ed with regard to the staining intensity 
as –, +, ++, or +++. Since  antibody 104–9 stained a higher proportion of the samples, the 
cutoff values chosen were also higher, 80% (lowest quartile, I) and 83% (median, II).  
8.1.1. Association between syndecan-1 expression and survival
Strong syndecan-1 expression was associated with favourable overall survival in patients 
with head and neck cancer (I and V) and among those diagnosed with lung cancer of the 
squamous cell type (II) (TABLE 3). The 2-year survival rates associated with cancers 
with a high and a low syndecan-1 expression were 72% vs. 50% (P=0.001), 84% vs. 63% 
(P=0.026), and 89% vs. 50% (P=0.027) in studies I, II, and V, respectively. When antibody 
104–9 was used for detection of syndecan-1, a similar result was found among patients 
with head and neck carcinoma in study I (66% vs. 47%, P=0.02), but not among patients 
with lung cancer in study II (P=0.60). When the largest subgroup of patients examined in 
study I, the laryngeal carcinoma patients, were analysed separately for survival, we found 
high syndecan-1 expression as detected with the B-B4 antibody  to be associated with 
more favourable prognosis (P=0.04). In study I syndecan-1 expression was an independent 
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TABLE 3. Syndecan-1 expression in cancer tissue
B-B4 immunostaining
Squamous cell head and neck cancer Study I
No. of patients
Positive for syndecan-1(N/%)
Median value
Cutoff value in survival analyses
Prognostic factor in univariate analysisa
Prognostic factor in multivariate analysisa
175
165/94%
50% (range, 0–100%)
50%
yes: P=0.001
yes: P=0.016
Squamous cell lung cancer Study II
No. of patients
Positive for syndecan-1 (N/%)
Median value
Cutoff value in survival analyses
Prognostic factor in univariate analysisa
Prognostic factor in multivariate analysis
116
83/72%
10% (range, 0–70%)
10%
yes: P=0.026
no
Non-small cell lung cancer Study III
No. of patients
Positive for syndecan-1 (N/%)
Scoring scale for expression
Prognostic factor in univariate analysis
45
34/76%
–/+/++/+++
no
Squamous cell head and neck cancer Study V
No. of patients
Positive staining for syndecan-1 (N/%)
Median value
Cutoff value in survival analyses
Prognostic factor in univariate analysisa
27
22/89%
15% (range, 0–95%)
10% (lowest tertile)
yes: P=0.027
104–9 immunostaining
Squamous cell head and neck cancer Study I
No. of patients
Positive for syndecan-1 (N/%)
Median value
Cutoff value in survival analyses
Prognostic factor in univariate analysisa
Prognostic factor in multivariate analysisa
175
172/98%
100% (range, 0–100%)
80% (lowest quartile)
yes: P=0.02
yes: P=0.03
Squamous cell lung cancer Study II
No. of patients
Positive for syndecan-1 (N/%)
Median value
Prognostic factor in univariate analysis
116
109/94%
83% (range, 0–100%)
no
aHigh (>cut-off value) syndecan-1 expression associated with favourable overall survival.
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prognostic factor in  multivariate analysis when antibody B-B4 was used (RR 1.9, 95% CI 
1.2–3.1), and also when antibody 104–9 was used (RR 1.7, 95% CI 1.1–2.6).
8.1.2. Correlation of syndecan-1 expression with other clinicopathological 
variables
In study I head and neck cancer cells were more often positive for syndecan-1 (B-B4) 
when cancer was well- or moderately differentiated than when it was poorly differentiated 
(P<0.0001). Strong syndecan-1 expression was also associated with a low clinical stage 
(stage 1–2 vs. 3–4, P<0.0001), lack of lymph node metastases (N0 vs. N1-3; P=0.0006), 
and a small primary tumour size (T1-2 vs. 3-4, P=0.02). When this series was stained with 
antibody 104–9, low syndecan-1 expression (≤80%) was strongly associated with a low 
histological grade (P<0.0001) and also with the male gender (P=0.03). No other statistically 
signifi cant associations were found between syndecan-1 expression and clinicopathological 
factors in this study. 
In study II high syndecan-1 expression (>10%, as detected with the B-B4 antibody) was 
strongly associated with high histological differentiation of lung cancer (Gr. I vs. Gr. II vs. 
Gr. III, P=0.001). A similar result was obtained when staining was done using antibody 
104–9 (P<0.0001). Patients who were older than the median age (62 years) at the time of 
the diagnosis of lung cancer had tumours with strong syndecan-1 expression more often 
than those who were younger (P=0.016). No signifi cant association between syndecan-1 
expression and the primary lung tumor size, nodal status or stage was found, although 
smaller tumours tended to be more often syndecan-1 positive in B-B4 staining (T1 vs. 
T2-4, P=0.08). In study III patients who had lung cancer with low syndecan-1 expression 
(– or +) had lower serum bFGF levels than patients who had lung cancer with a stronger 
syndecan-1 expression (++ or +++; median, 1.2 pg/mL; vs. median, 3.6 pg/mL, respec-
tively, P=0.018). In study V, which comprised a small series of patients who had laryngeal 
cancer, no signifi cant associations between syndecan-1 expression in tissue samples and the 
clinicopathological factors examined were found, possibly due to the low statistical power 
and the type of cancer studied.  
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8.2. Soluble syndecan-1 (III, IV, V)
The median pretreatment serum syndecan-1 levels in the cancer patients of studies III to 
V ranged from 41 ng/mL to136 ng/mL. In studies III and IV the lung cancer patients had 
statistically higher pretreatment serum syndecan-1 levels as compared to the controls who 
had medium levels of 16 ng/mL (range, from 0 ng/mL to 213 ng/mL) and 17 ng/mL (0–308 
ng/mL), respectively (P<0.0001, in both cases).
8.2.1. Serum syndecan-1 as a prognostic factor in carcinomas of the head 
and neck and the lung
In study III that consisted of a series of 184 lung cancer patients, high serum syndecan-1 
levels were associated with poor outcome (TABLE 4). When the median serum syndecan-1 
ectodomain concentration (41 ng/mL) was taken as the cutoff value, patients with higher 
than the median serum level had a median survival time of 6 months as compared with 11 
months in patients who had serum levels lower than the median (P=0.003). When the high-
est tertile level was used as the cutoff value, the median survival time of the patients with 
a higher serum level than the cutoff value was only 4 months as compared to 11 months 
among the rest of the patients (P=0.0001). These fi ndings remained similar when the medi-
an or upper tertile serum syndecan-1 levels were used as cutoff values among the subsets of 
patients with NSCLC or SCLC (TABLE 4). In study IV high serum syndecan-1 levels cor-
related with favourable overall survival when the levels corresponding to the upper tertile 
(212 ng/mL) or upper quartile (283 ng/mL) were chosen as the cutoff levels (TABLE  4). In 
study V that comprised 44 patients with squamous cell head and neck cancer, pretreatment 
serum syndecan-1 level did not correlate signifi cantly with overall survival, but patients 
whose serum syndecan-1 decreased ≥10% from the pretreatment level had more favourable 
survival than those whose levels remained stable or increased (P=0.0069). In multivariate 
analyses the pretreatment serum syndecan-1 level turned out to be an independent prognos-
tic factor both in NSCLC (study III, P= 0.011, RR 1.8, 95% CI 1.1–3.1) and in SCLC (study 
IV, P=0.044, RR 1.68, 95% CI 1.02–2.77). 
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TABLE 4. Association of pretreatment serum syndecan-1 level with overall 
survival in univariate analyses
Lung cancer, local and metastatic 
(Study III)
N 1-yr survival 
%
5-yr survival 
%
P
Lung cancer, all
 ≤41 ng/mL (median)
 >41 ng/mL
 ≤59 ng/mL (upper tertile)
 >59 ng/mL 
NSCLC
 ≤40 ng/mL (median)
 >40 ng/mL
 ≤54 ng/mL (upper tertile)
 >54 ng/mL
NSCLC (squamous cell)
 ≤40 ng/mL (median)
 >40 ng/mL
 ≤54 ng/mL (upper tertile)
 >54 ng/mL
NSCLC (adenocarcinoma)
 ≤38 ng/ml (median)
 >38 ng/mL
 ≤53 ng/mL (upper tertile)
 >53 ng/mL
SCLC
 ≤44 ng/mL (median)
 >44 ng/mL
 ≤84 ng/mL (upper tertile)
 >84 ng/mL
94
90
1231
61
69
69
92
46
43
39
55
27
23
21
30
14
23
23
31
15
48
33
49
25
54
36
51
33
58
44
58
37
48
19
43
14
30
26
35
13
18
10
19
 7
23
13
22
11
23
18
24
15
22
 5
20
 0
 4
 4
 3
 7
0.003
0.0001
0.0085
0.0038
0.11
0.029
0.0067
0.0021
0.29
0.041
Small cell lung cancer, mostly 
metastatic (Study  IV)
N
 
1-yr survival 
%
2-yr survival 
%
P
 
SCLC, all
 <136 ng/mL (median)
 ≥136 ng/mL
  <212 ng/mL (upper tertile)
 ≥212 ng/mL
 <283 ng/mL (upper quartile)
 ≥283 ng/mL
45
43 
59
29
66
22
51
44
58
38
56
36
20
16
25
 3
22
 3
0.44
0.0034
0.0046
Head and neck cancer 
(Study V)
N
 
1-yr survival 
%
2-yr survival
%
P
 <75 ng/mL (median)
 ≥75 ng/mL
 22
 22
96
82
75
73 0.53
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8.2.2. Associations between serum syndecan-1 level and 
clinicopathological factors
Patients with a high Karnofsky’s performance status tended to have lower pretreatment se-
rum syndecan-1 values than those with a low performance status (studies III and IV; K≤70 
vs. K>70, P=0.0011; K≤70 vs. >70, P=0.021; respectively). In study III high pretreatment 
serum syndecan-1 level was also associated with a large lung cancer mass (stage IIIB or 
stage IV disease, P=0.0004). A weak positive association was found between serum synde-
can-1 and bFGF levels (P=0.044, Spearman correlation coeffi cient). No such association 
was found between the serum syndecan-1 levels and gender, age at diagnosis, histological 
grade, histological type, or serum CEA levels at the time of lung cancer diagnosis. In study 
IV patients with high serum syndecan-1 level had frequently higher than normal pretreat-
ment serum lactate dehydrogenase (LDH) levels (P=0.0024). In study V head and neck 
carcinoma patients with a high pretreatment serum syndecan-1 level tended to have a high 
pretreatment bFGF serum level (P=0.077; Spearman correlation coeffi cient). 
8.3. Clinical signifi cance of serum bFGF level in carcinomas of the 
head and neck and the lung (III, V)
The median pretreatment bFGF level in lung cancer patients was 2.2 pg/mL (range, from 0 
to 62.6 pg/mL, study III), and there was no signifi cant difference in the serum bFGF levels 
between patients with NSCLC and those with SCLC (median 2.3 pg/mL; range, from 0 
to 62.6 pg/mL vs. median 1.8 pg/mL; range, from 0 to 8.6 pg/mL, respectively; P=0.32). 
These levels are similar to the levels found in the sera of patients with non-Hodgkin’s lym-
phoma (Salven et al., 2000). 
In general, high serum bFGF levels tended to be associated with poor outcome (TABLE 
5). When the upper tertile (3.4 pg/mL) was chosen as the cutoff value among lung cancer 
patients (study III), patients who had levels higher than the cutoff value had worse outcome 
than those with lower serum bFGF levels (P=0.023). The 1- and 5-year survival rates in 
these groups were 23% and 7%, and 47% and 14%, respectively. When the associations of 
serum bFGF with survival were investigated within histological subtypes of NSCLC, high 
bFGF levels were associated with poor outcome in adenocarcinoma (n=30, median level 
4.1 pg/mL used as cutoff value, P=0.0031), but not in squamous cell carcinoma (n=61, 
P=0.45). No signifi cant association between serum bFGF levels and survival was found 
among patients with SCLC (n=27, P=0.74). When the serum bFGF level corresponding to 
the highest tertile (3.4 pg/mL) was used as the cutoff value, patients with a poor perform-
ance status and those with NSCLC tended to have high serum levels (P=0.05 and P=0.054, 
respectively). NSCLC patients with adenocarcinoma had higher levels than those with sq-
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uamous cell cancer (P=0.027). Gender, age, stage, serum CEA levels, or the histological 
grade were not associated with serum bFGF levels. These results need, however, be inter-
preted with caution due to the relatively small numbers of patients in these analyses. 
The median serum bFGF level was 4.6 pg/mL (range, from 0.2 to 63.6 pg/mL) among 
patients with squamous cell head and neck carcinoma (V). High pretreatment serum bFGF 
levels were associated with poor overall survival (P=0.043; TABLE 5) and marginally with 
poor disease-free survival in head and neck cancer (P=0.07). Patients with higher than the 
median serum bFGF level had an 82% 1-year and a 63% 2-year survival rate as compared 
to survival rates of 96% and 86%, respectively, among the subset of patients who had a 
serum bFGF level lower than the median. Pretreatment serum bFGF level did not correlate 
signifi cantly with any other clinicopathological factor investigated in the series, but the 
number of patients available for analysis was relatively small (n=44).
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TABLE 5. Association of serum pretreatment bFGF level with overall survival in uni-
variate analyses
Lung cancer (Study III) N
 
1-yr 
survival %
5-yr 
survival %
P
Lung cancer, all
 ≤2.2 pg/mL (median)
 >2.2 pg/mL
 ≤3.4 pg/mL (upper tertile)
 >3.4 pg/mL
NSCLC
 ≤2.3 pg/mL (median)
 >2.3 pg/mL
 ≤4.1 pg/mL (upper tertile)
 >4.1 pg/mL
NSCLC, squamous cell carcinoma
 ≤2.1 pg/mL (median)
 >2.1 pg/mL
 ≤2.8 pg/mL (upper tertile)
 >2.8 pg/mL
NSCLC, adenocarcinoma
 ≤4.1 pg/mL (median)
 >4.1 pg/mL
 ≤5.1 pg/mL (upper tertile)
 >5.1 pg/mL
SCLC
 ≤1.8 pg/mL (median)
 >1.8 pg/mL
 ≤2.9 pg/mL (upper tertile)
 >2.9 pg/mL
65
61
86
43
51
48
66
33
31
30
41
20
15
15
21
 9
14
13
18
 9
46
31
47
23
53
33
56
18
52
43
54
35
60
13
43
22
29
15
28
11
14
10
14
 7
20
10
21
 3
19
13
22
 5
20
 0
14
 0
 0
 0
 0
 0
0.16
0.023
0.082
0.0002
0.43
0.15
0.0031
0.12
0.74
0.67
Head and neck cancer (Study V) N
 
1-yr 
survival %
2-yr 
survival %
P
 
SCC of the head and neck
 <4.6 pg/mL (median)
 ≥4.6 pg/mL
 <6.3 pg/mL (mean)
 ≥6.3 pg/mL
22
22
31
13
96
82
94
77
86
63
83
53
0.043
0.034
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8.4. Effect of treatment on serum syndecan-1 levels in head and 
neck carcinoma (V)
Serum syndecan-1 levels decreased after the locoregional treatment of cancer as compared 
to the pretreatment levels. The median serum level in samples collected 3 months after the 
treatment was 58 ng/mL as compared to the baseline level of 75 ng/mL (n=41, Spearman 
rank correlation, P<0.0001). Those patients whose serum syndecan-1 level decreased over 
10% (n=26) from the pretreatment level had a better overall survival than patients with 
stable or increasing serum syndecan-1 value (n=16, P=0.0069) with 2-year survival rates of 
92% and 51%, respectively. Similarly, patients with decreased (>10%) serum syndecan-1 
levels also had higher disease-free survival rates than the rest of the patients (P=0.0091). 
Although based on a retrospective analysis and a small cohort of patients, these fi ndings 
suggest that some serum syndecan-1 may originate from the tumour, and that serum synde-
can-1 deserves to be further evaluated in monitoring of treatment of head and neck cancer.
A transient rise of the serum syndecan-1 levels was found in the serum samples collected 
during the second week of the radiotherapy course as compared to the pretreatment lev-
els among patients treated with radiotherapy (n=19, V). Ten of these patients had serum 
samples taken prior to, during, and after radiotherapy. Among these patients the median 
pretreatment serum syndecan-1 level was 74 ng/mL, 87 ng/mL during the second week of 
the radiation therapy course (P=0.0096), and 60 ng/mL 3 months after completion of treat-
ment (P=0.0073 as compared with the baseline). In study V 12 patients relapsed during the 
follow-up, and a serum sample taken at progression was available from 9 of these patients. 
The median serum syndecan-1 level was 76 ng/mL (range, 23 to 274 ng/mL) at the time of 
cancer progression while the median level was 52 ng/mL when measured 3 months after 
treatment of the primary tumour in these 9 cases (P=0.05), which provides further support 
to the hypothesis that serum syndecan-1 levels may increase in parallel with head and neck 
cancer progression.  
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9. DISCUSSION
9.1. Methodological aspects of syndecan-1 immunoassay and 
immunohistochemistry
Human syndecan-1 ELISA was used to determine serum syndecan-1 concentrations in
studies III to V (Table 5).  All analyses and calibration were carried out similarly in each 
study. However, the median serum syndecan-1 values varied between the studies. In study 
III that involved 184 lung cancer patients, the median value was 41 ng/mL in the entire 
series and was similar in the subgroups of NSCLC and SCLC patients (40 ng/mL and 44 ng/
mL, respectively). In study IV where the study population consisted only of   SCLC patients 
the median level was higher, 136 ng/mL. The majority of the patients (98%) in study IV had 
stage III or IV cancer (stage IV corresponds to overtly metastatic disease), while in study 
III 72% of all the NSCLC patients and 82% of the patients with SCLC had stage III or IV 
disease. In study V, involving patients with SCC of the head and neck and with relatively a 
favourable prognosis, the median level was 75 ng/mL. Thus, patients in each study had dif-
ferent histological types of tumour with different sizes, and variable proportions of patients 
with metastatic disease, which may infl uence median soluble syndecan-1 values. 
Little is known about the infl uence of long-term storage on serum syndecan-1 values. Sera 
used in study III had been stored at –20oC, while the sera assessed in studies IV and V had 
been stored at –70oC. The effect of the storage temperature and duration on syndecan-1 
immunoreactivity requires further study. In a series consisting of myeloma patients the 
reported median value for serum syndecan-1 was 165 ng/mL (Seidel et al., 2000a), which 
is in the same range as the values measured by us in patients with lung cancer or head and 
neck cancer. These authors found the median serum syndecan-1 value to be 128 ng/mL, 
which is higher than the median value of 17 ng/ml and 18 ng/mL found by us in the control 
groups of studies III and IV. Serum syndecan-1 analyses have thus far been used for a few 
research purposes only, and little is known how the serum concentrations might vary with 
respect of age, gender, or in different pathological conditions. 
We studied syndecan-1 expression in paraffi n-embedded tumour samples by immunohisto-
chemistry using both a mouse monoclonal antibody against human syndecan-1 B-B4 (I–III, 
V) and a rat monoclonal anti-human syndcan-1 antibody 104–9 (I, II). Although a majority 
of tumours showed at least some positive staining with either antibody (72% to 94% with 
B-B4 and 94%–98% with 104–9), detection of syndecan-1 expression was very different 
with the 2 antibodies. The median percentage values of positive staining ranged from 10% 
to 50% with B-B4 and from 83% to 100% with 104–9 (Table 3). 
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9.2. Syndecan-1 expression in tumour samples and its prognostic 
value 
Head and neck carcinoma 
SCCs of the head and neck frequently recur at the locoregional sites, and development of 
second primary tumours is not uncommon (Carter, 1991; Dreyfuss and Clark, 1991). The 
Tumour-Node-Metastasis (TNM) classifi cation that refl ects the tumour volume is probably 
still the strongest prognostic factor in SCC of the head and neck, while biological markers 
have had relatively little signifi cance in the management of the disease (Carter, 1991). To 
this background it is of interest that strong syndecan-1 expression detected by immunohis-
tochemistry has been consistently found to be associated with favourable survival as in a 
series comprising 29 patients with SCC of the head and neck (Inki et al., 1994c), in another 
series of 98 patients with SCC of larynx (Pulkkinen et al., 1997) as well as in the present 
series involving 202 patients with SCC of the head and neck. Syndecan-1 (as detected with 
B-B4) expression was associated with favourable overall survival in both univariate (I,V) 
and multivariate (I) survival analyses, and expression was also associated with a small pri-
mary tumour size, lack of nodal metastases, and a high histological grade of differentiation 
(I). Similar results were obtained also with antibody 104-9 (I). 
In contrast with the consensus in most other types of human cancer, the value of histologi-
cal grading as a prognostic factor in SCC of the head and neck is still considered  contro-
versial by many. In some studies grading has been found to have prognostic value (e.g. Pera 
et al., 1986; Wiernik et al., 1991), while others report no such value (e.g. Bundgaard et al., 
1992). The present fi ndings were somewhat discordant. In study I the histological grade 
was a strong prognostic factor in a univariate analysis. No signifi cant association between 
grading and survival was found in study V, but this series was small in size and consisted 
mainly of small larynx tumours. Histological grading, though it generally predicts outcome 
relatively well, is subjective and often diffi cult to reproduce (Bundgaard et al., 1992). We 
found syndecan-1 expression to be strongly associated with histological grade (I); well 
differentiated carcinomas more often showed strong syndecan-1 expression than poorly 
differentiated ones. Interestingly, in one multivariate analysis syndecan-1 was an independ-
ent prognostic factor while histological grade had no independent value (I). This result sug-
gests that syndecan-1 expression may be a stronger prognostic indicator than histological 
grading, but this needs to be confi rmed in future studies.
Lung cancer 
Expression of syndecan-1 is often altered in cancer, and it has been suggested that loss 
of syndecan-1 expression in carcinomas accompanies the malignant phenotype (Inki and 
Jalkanen, 1996; Sanderson, 2001) although results at variance with this have also been 
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published (Hirabayashi et al., 1998). As in SCC of the head and neck, histological grading 
may not be a strong prognostic factor in lung cancer, but several studies show that poor 
histological differentiation is an adverse prognostic factor in NSCLC (Lipford et al., 1984; 
Takise et al., 1988; Ichinose et al., 1995). Other commonly accepted adverse prognostic 
factors in lung cancer include advanced stage and age over 60 at diagnosis, male gender, a 
poor performance status, and weight loss, but many other factors may also be of importance 
(Nishio et al., 1996; Pastorino et al., 1997; Adachi et al., 1998; Volm et al., 1998; Tanaka et 
al., 1999; Junker, 2001; Yuan et al., 2001; Mattern et al., 2002; Jeremic et al., 2003). 
Syndecan-1 expression turned out to be a strong prognostic factor in a univariate analysis of 
the series of 116 patients with SCC of the lung (II). As in head and neck cancer, we found a 
strong association between syndecan-1 expression and histological grading in lung cancer, 
whereas no association was found with the clinical stage. In study III we did not detect an 
association between tissue expression of syndecan-1 and survival. However, we were not 
able to assess the tissue expression of syndecan-1 in this study in full. The tissue samples 
available for analysis in this series were often small in size, and were entirely lacking for a 
large proportion of patients creating the possibility of  selection bias. The scale of immunos-
taining classifi cation used (–/+/++/+++ instead of percentage of positively staining cells) 
was also crude in this study due to the poorer quality of the tissue starting material avail-
able. Since adjuvant therapies are being increasingly used in NSCLC, it is of importance to 
discover new prognostic factors and predictive factors for chemotherapy and radiotherapy 
effi cacy. In general, the present results suggest that high cell surface syndecan-1 expres-
sion is associated with favourable survival in SCC of the lung, and that tissue expression of 
syndecan deserves further study as a novel prognostic factor in lung cancer.
9.3. Clinical signifi cance of soluble syndecan-1
The function and prognostic signifi cance of serum syndecan-1 in different types of human 
cancers has not been fully investigated. High levels of shed syndecan-1 have been found to 
be associated with poor outcome in multiple myeloma (Seidel et al., 2000a; Kyrtsonis et al., 
2004), but no other data is available on the role of soluble syndecan-1 as a prognostic factor. 
After evaluating syndecan-1 expression in head and neck and lung carcinomas by immuno-
histochemistry we were interested in investigating whether serum syndecan-1 levels would 
be associated with survival in the same carcinomas.
In our series of lung cancer patients a high pretreatment serum syndecan-1 level was as-
sociated with poor overall survival in univariate analyses (III, IV), and had an independent 
infl uence on survival in a multivariate analysis in NSCLC (III) and in SCLC (IV). Patients 
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with a poor performance status (III, IV) and in study III those with a large tumour mass 
tended to have high syndecan-1 serum levels. Since the performance status tends to de-
crease in parallel with cancer growth, a poor performance status may also in part refl ect the 
overall tumour volume. In study IV patients with SCLC and a high lactate dehydrogenase 
level at diagnosis also frequently had a high syndecan-1 serum level. LDH is a strong ad-
verse prognostic factor in SCLC together with the clinical stage and the performance status 
(Stokkel et al., 1998; Yip and Harper, 2000). In the present series it was not signifi cantly as-
sociated with prognosis, suggesting that serum syndecan-1 might be a stronger prognostic 
factor in SCLC than the lactate dehydrogenase level.
In study V on SCC of the head and neck, pretreatment serum syndecan-1 levels were not as-
sociated with overall survival, but the size of the series and the limited number of endpoints 
prohibits drawing fi rm conclusions on the prognostic value of pretreatment serum synde-
can-1 levels in head and neck carcinoma. However, serum syndecan-1 levels decreased 
following locoregional treatment of cancer and a decrease in the serum levels following 
primary cancer treatment turned out to be a prognostic factor; a decrease of 10% or more 
from the pretreatment level was associated with a favourable outcome.  Measurement of 
syndecan-1 levels might thus be helpful in monitoring for treatment response and selection 
of patients who might benefi t from additional treatments. However, the percent changes in 
the syndecan-1 serum levels were not in general large, and the factors affecting the normal 
variation of the syndecan-1 levels remain inadequately studied, suggesting that serum syn-
decan-1 levels cannot be recommended at present for monitoring of treatment response in 
the clinical setting. 
The origin of shed syndecan-1 is not known. Some of the circulating soluble syndecan-1 
might have its origin in the tumour tissue, and our results are in line with this hypothesis. 
A transient rise in the serum syndecan-1 levels on the second week of radiotherapy is also 
compatible with this hypothesis, since soluble syndecan-1 might be released from cancer 
cells undergoing apoptosis as a result from radiation therapy. In a recent study on a series of 
50 patients diagnosed with multiple myeloma, a signifi cant decrease in the median serum 
syndecan-1 levels was found among patients who responded to chemotherapy, whereas no 
change took place in patients who did not respond to chemotherapy (Janosi et al., 2004). 
Similarly, Aref et al. (2003) concluded, in a study with 25 newly diagnosed myeloma pa-
tients, that soluble syndecan-1 was signifi cantly higher in non-responders to chemotherapy 
as compared to responders, and a high level of soluble syndecan-1 was a negative prognos-
tic factor. They also found that cellular and soluble syndecan-1 consentrations correlated 
inversely. In one series of 60 patients with SCC of the oral cavity increased syndecan-1 
tissue expression in immunohistochemistry after induction chemotherapy predicted good 
outcome (Nemeth et al., 2005).
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Many soluble putative tumour markers have been evaluated in SCC of the head and neck, 
but despite some promise most markers neither normalize following treatment nor become 
elevated at the time of tumour recurrence (Maxim and Veltri, 1986; Mevio et al., 1991; 
Kimura et al., 2000; Homer et al., 2002; Tartour et al., 2001; Yazici et al., 2001; Shang et 
al., 2002). An example of such a marker is SCC antigen, the levels of which were associated 
with disease recurrence in a series of 70 patients with laryngeal cancer (Lachowicz et al., 
1999). Another example is cathepsin L, the serum levels of which were evaluated in a series 
of 42 patients with SCC of the head and neck, and the risk of disease recurrence and death 
were signifi cantly associated with serum cathepsin L levels (Strojan et al., 2001). 
As in SCC of the head and neck, many studies have addressed the clinical value of soluble 
serum markers in NSCLC and SCLC. Most studies have focused on pretreatment serum 
levels of the marker (Ardizzoni et al., 2001; Buccheri and Ferrigno, 2002; Laack et al., 
2002; Neuner et al., 2002; Pujol et al., 2003; Sasaki et al., 2003), and markers have also 
been evaluated for monitoring of treatment effi cacy. Perhaps the most extensively evalu-
ated serum marker in lung cancer is  carcinoembryonic antigen (CEA), which is commonly 
used to assess treatment response. For example, in one series comprising 297 patients with 
stage I NSCLC, serum CEA level was found to be a useful predictor of survival, and a per-
sistently high CEA level after treatment was a strong indicator of poor prognosis (Sawabata 
et al., 2002). In another study on patients with NSCLC survival rate was higher among 
patients who had elevated serum SCC antigen and who became antigen-negative following 
resection than among patients who remained antigen-positive (Takeuchi et al., 2003). Stud-
ies where serum syndecan-1 is directly compared to CEA and other existing serum markers 
used to monitor lung cancer treatment are now needed. 
9.4. Clinical signifi cance of serum bFGF level 
Angiogenesis is essential for tumour growth and dissemination (Folkman, 1990). One of 
the several growth factors implicated in angiogenesis is  bFGF, which is expressed by most 
tumours (Folkman and Klagsbrun, 1987; Nanus et al., 1993; Ohta et al., 1995; Riedel et 
al., 2000). Elevated serum bFGF levels have been detected in patients with various types of 
cancer; in patients with non-Hodgkin’s lymphoma, melanoma, lung cancer and myeloma 
elevated serum bFGF levels correlate with poor prognosis (Graeven et al., 1999; Dietz et 
al., 2000; Ueno et al., 2001; Ugurel et al., 2001; Brattström et al., 2002; Ruotsalainen et 
al., 2002; Bentas et al., 2003; Kyrtsonis et al., 2004). In line with most previous studies we 
found the pretreatment serum bFGF level to be associated with poor outcome in NSCLC 
(III) and SCC of the head and neck (V). 
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Pretreatment serum bFGF levels did not signifi cantly correlate with the clinical stage, which 
is in line with several prior studies (Ueno et al., 2001; Brattstöm et al., 2002; Homer et al., 
2002; Ruotsalainen et al., 2002). However, opposing fi ndings have been reported in renal 
cell carcinoma, melanoma, and hepatocellular carcinoma, where elevated serum bFGF lev-
els were associated with advanced disease stages and the tumour burden (Dosquet et al., 
1997; Poon et al., 2001; Ugurel et al., 2001). In one study bFGF expression as detected by 
immunohistochemistry, was associated with  stage in NSCLC (Takanami et al., 1996). 
Pretreatment serum bFGF levels had independent prognostic infl uence in NSCLC in a mul-
tivariate model. In SCC of the head and neck it turned out to be a prognostic factor in 
univariate analysis. Although we could not perform multivariate analysis in study V due 
to the limited size of the series, the results suggest that pretreatment serum bFGF level is a 
prognostic factor both in NSCLC and in SCC of the head and neck.
Serum bFGF levels may decrease after treatment of cancer (George et al., 2002; Ria et 
al., 2004), supporting the contention that some of the soluble bFGF originates from the 
tumour tissue. Syndecan-1 functions as a co-receptor of the bFGF receptors, and binds 
bFGF with less avidity than the light affi nity receptors. Presence of increased amounts of 
soluble syndecan-1 may be associated with an adverse outcome, because elevated levels of 
soluble syndecan-1 may carry larger amounts of bFGF in the blood circulation and deliver 
it more effectively to the tumour deposits. The role of syndecan-1 in bFGF signaling is 
controversial and the literature reports are confl icting. One study identifi ed syndecans to 
inhibit bFGF signaling, whereas in an other study syndecans were found to promote bFGF 
signaling (Aviezer et al., 1994; Steinfeld et al., 1996).
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10. SUMMARY AND CONCLUSIONS
The main conclusions of the present study are:
1. Decreased expression of syndecan-1 is associated with low histological grade of 
differentiation and poor outcome in SCCs of the head and neck and in lung cancer. 
Syndecan-1 is a novel prognostic factor in both cancer types. 
2. High serum syndecan-1 levels may be measured in patients with lung cancer or SCC 
of the head and neck prior to cancer treatment. In general, high serum levels are as-
sociated with a poor outcome in lung cancer.
3. Patients with squamous cell head and neck cancer whose serum syndecan-1 levels 
decrease following cancer treatment may have a more favourable clinical outcome 
than patients who have stable or increasing serum syndecan-1 levels in longitudinal 
follow-up. 
4. High pretreatment serum bFGF level is associated with poor outcome in patients 
with NSCLC or SCC of the head and neck. 
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